Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.9 %
ROCE
-532.2 %
P/E Ratio
0.4
P/B Ratio
0.3
Industry P/E
--
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.7
Face value
--
Shares outstanding
3,183,426
CFO
$-79.21 Mln
EBITDA
$-98.74 Mln
Net Profit
$-84.63 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Avenue Therapeutics (ATXI)
| -- | -- | -- | -- | -29.5 | -66.1 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|
|
Avenue Therapeutics (ATXI)
| 1,117.0 | -86.1 | -84.7 | -38.0 | 77.8 | 48.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Avenue Therapeutics (ATXI)
|
0.4 | 0.9 | 1.4 | -3.7 | 150.4 | -104.9 | 0.4 | 0.3 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical... trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Read more
CEO & Director
Dr. Alexandra MacLean M.D.
CEO & Director
Dr. Alexandra MacLean M.D.
Headquarters
Bay Harbor Islands, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Avenue Therapeutics Inc (ATXI) is $0.41 (NASDAQ) as of 02-Apr-2026 10:25 EDT. Avenue Therapeutics Inc (ATXI) has given a return of -29.55% in the last 3 years.
The P/E ratio of Avenue Therapeutics Inc (ATXI) is 0.38 times as on 27-Mar-2026.
The P/B ratio of Avenue Therapeutics Inc (ATXI) is 0.26 times as on 27-Mar-2026, a 93 discount to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.27
|
1.14
|
|
2023
|
-0.40
|
2.61
|
|
2022
|
-0.46
|
0.42
|
|
2021
|
-0.30
|
0.32
|
|
2020
|
-1.29
|
2.78
|
The 52-week high and low of Avenue Therapeutics Inc (ATXI) are Rs 0.41 and Rs 0.41 as of 05-Apr-2026.
Avenue Therapeutics Inc (ATXI) has a market capitalisation of $ 1 Mln as on 27-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Avenue Therapeutics Inc (ATXI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.03
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.